Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal, Podiatry, Diabetes |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 8/9/2018 |
| Start Date: | June 2015 |
| End Date: | June 2019 |
| Contact: | Tara Kristof |
| Email: | tara.kristof@utsouthwestern.edu |
| Phone: | 214-648-9007 |
This is a pilot study. Maximum 30 subjects with a diabetic foot ulcer (DFU) or surgical foot
wound will be consented in order to have 20 eligible subjects who will be enrolled and
completed the study. Study duration will be three weeks. Patients will be consented and
undergo debridement as standard of care at day 0. Ankle-Brachial Index (ABI), Monofilament
Sensory Test and Vibration Perception Threshold(VPT) test will be performed only at day 0.
Tissue samples will be taken at this visit during standard of care wound debridement and
these tissue samples of the wound would normally be removed as part of routine debridement.
These tissue samples of the wound will be used for gene expression and bacterial
analysis(research). The patient will then receive topical oxygen therapy using the
Transcutaneous O2 device (research) with moist wound dressings for 21 days. Moist wound
dressings are used as standard of care. Treatment will be initiated during Screening/Baseline
visit(day 0) after routine wound debridement, and patient will receive instructions for home
use of the device. The patient will be seen for routine wound debridement at days 7, 14, and
21 with a study window of 5 days., Digital photos of the wound, and vascular evaluations
(Transcutaneous oxygen measurements and Hyperspectral imaging. will be performed at each
study visit(research). Tissue samples will be taken during standard of care wound debridement
at every study visit. Results of the data analysis from this project will be used to inform
the design of a larger randomized clinical trial.
wound will be consented in order to have 20 eligible subjects who will be enrolled and
completed the study. Study duration will be three weeks. Patients will be consented and
undergo debridement as standard of care at day 0. Ankle-Brachial Index (ABI), Monofilament
Sensory Test and Vibration Perception Threshold(VPT) test will be performed only at day 0.
Tissue samples will be taken at this visit during standard of care wound debridement and
these tissue samples of the wound would normally be removed as part of routine debridement.
These tissue samples of the wound will be used for gene expression and bacterial
analysis(research). The patient will then receive topical oxygen therapy using the
Transcutaneous O2 device (research) with moist wound dressings for 21 days. Moist wound
dressings are used as standard of care. Treatment will be initiated during Screening/Baseline
visit(day 0) after routine wound debridement, and patient will receive instructions for home
use of the device. The patient will be seen for routine wound debridement at days 7, 14, and
21 with a study window of 5 days., Digital photos of the wound, and vascular evaluations
(Transcutaneous oxygen measurements and Hyperspectral imaging. will be performed at each
study visit(research). Tissue samples will be taken during standard of care wound debridement
at every study visit. Results of the data analysis from this project will be used to inform
the design of a larger randomized clinical trial.
Patients seen at the University of Texas (UT) Southwestern Wound Clinic with a diabetic foot
wound will be identified, consented, and screened for the study. Upon signing consent,
patients will be assigned a unique screening number. The screening number given to the first
patient will be 01 and increasing sequentially with each subject screened. Screened subjects
will be entered onto a screening log. Once a number is assigned it cannot be re-assigned to
another subject.
At Day 0, a vascular evaluation including ABI, Sensilase, Transcutaneous oxygen measurements,
and hyperspectral imaging will be performed. Monofilament Sensory Test and Vibration
Perception Threshold(VPT) test will also be performed at day 0.Patients will undergo standard
of care wound debridement. Tissue samples will be taken routinely as standard of care. A
wound assessment will be performed, including the debridement as standard of care, wound
measurements, and digital photos. Gene expression and bacterial analysis will be performed on
tissue samples. After tests are performed, patient will receive topical oxygen therapy using
the Transcutaneous O2 device with moist wound dressings. Moist wound dressings are used as
standard of care. Patient will receive instructions to continue treatment at home.
Patient will return for an appointment at days 7, 14, and 21, where vascular assessment
(Sensilase, Transcutaneous oxygen measurements, Hyperspectral imaging) ,wound assessment
(wound measurements, digital photos and acetate tracings) and tissue sampling will be
performed following standard of care debridement, Patient will cease topical oxygen treatment
at day 21, and study will be concluded.
wound will be identified, consented, and screened for the study. Upon signing consent,
patients will be assigned a unique screening number. The screening number given to the first
patient will be 01 and increasing sequentially with each subject screened. Screened subjects
will be entered onto a screening log. Once a number is assigned it cannot be re-assigned to
another subject.
At Day 0, a vascular evaluation including ABI, Sensilase, Transcutaneous oxygen measurements,
and hyperspectral imaging will be performed. Monofilament Sensory Test and Vibration
Perception Threshold(VPT) test will also be performed at day 0.Patients will undergo standard
of care wound debridement. Tissue samples will be taken routinely as standard of care. A
wound assessment will be performed, including the debridement as standard of care, wound
measurements, and digital photos. Gene expression and bacterial analysis will be performed on
tissue samples. After tests are performed, patient will receive topical oxygen therapy using
the Transcutaneous O2 device with moist wound dressings. Moist wound dressings are used as
standard of care. Patient will receive instructions to continue treatment at home.
Patient will return for an appointment at days 7, 14, and 21, where vascular assessment
(Sensilase, Transcutaneous oxygen measurements, Hyperspectral imaging) ,wound assessment
(wound measurements, digital photos and acetate tracings) and tissue sampling will be
performed following standard of care debridement, Patient will cease topical oxygen treatment
at day 21, and study will be concluded.
Inclusion Criteria:
- Male or female subjects of all races and ethnicities, age 18-89
- Diagnosis of diabetes mellitus
- Has a diabetic foot ulcer
Exclusion Criteria:
- End-stage renal disease (ESRD)
- Has untreated foot ulcer at time of study
- HIV, hepatitis, autoimmune disease, Systemic lupus erythematous (SLE), Raynaud's
disease
- Ankle-Brachial Index (ABI) < 0.4
- Unable or unwilling to provide informed consent
We found this trial at
1
site
Click here to add this to my saved trials
